title: Preliminary Experience with Transdermal Oxybutynin Patches for Hyperhidrosis.
abstract: OBJECTIVE
  Hyperhidrosis is very common and has a considerable impact on patients' quality of life. While oral oxybutynin is associated with good response rates, adverse effects are common and frequently cause patients to stop treatment. Following the recent launch of oxybutynin in a transdermal patch formulation in Spain, we undertook a preliminary study to assess treatment response and adverse effects in patients with hyperhidrosis.
  
  
  METHODS
  This prospective study of 25 patients treated twice weekly with transdermal oxybutynin patches over 10 weeks assessed treatment response on 2 subjective scales: the Hyperhidrosis Disease Severity Scale (HDSS) and a visual analog scale (VAS) for sweating.
  
  
  RESULTS
  Sixty percent of patients showed an improvement in HDSS scores. VAS scores improved in all cases, and 68% of patients achieved a reduction of 3 points or more. Just 2 patients (8%) experienced treatment-related adverse effects (irritant dermatitis at the patch application site in both cases).
  
  
  CONCLUSIONS
  Although our results are based on a small sample, they suggest that transdermal oxybutynin could be a useful option for the treatment of hyperhidrosis and that it has an excellent safety and tolerability profile.
authors: Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, España. Electronic address: Mbergon1@yahoo.es.
authors: M
authors: M
authors: Bergón-Sendín
authors: Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, España.
authors: A
authors: A
authors: Pulido-Pérez
authors: Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, España.
authors: L C
authors: LC
authors: Sáez-Martín
authors: Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, España.
authors: R
authors: R
authors: Suárez-Fernández
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy*; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage*; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin
keywords: Hiperhidrosis; Hyperhidrosis; Oxibutinina; Oxybutynin; Tratamiento; Treatment